Parkinson’s disease (PD) is predominantly recognized as a motor disorder, but PD is also associated with a diverse mix of disabling nonmotor symptoms, including cognitive impairment and dementia. PD dementia is progressive and severely impacts QOL and independence, and most expert neurologists interviewed by DRG cite dementia as having the greatest unmet need for new therapeutics among all PD nonmotor symptoms. Available antidementia agents (mostly prescribed off-label) are largely ineffective. Opportunity for premium pricing and limited competition has recently spurred industry activity in this arena and a number of novel agents are in early-phase development. Understanding current management strategies, prevailing market access factors, and the market outlook for PD dementia is crucial for developers advancing new drugs for this understudied and underdeveloped market space.
Geography: United States
Primary research: 6 KOL interviews in Q1 2019
Key companies covered: Adamas, Allergan, Alkahest, Anavex, Eli Lilly, IRLAB
Key drugs covered: Rivastigmine, donepezil, galantamine, memantine, Namzaric, GRF6019/6021, ANAVEX 2-73, LY3154207, IRL752